Long-term treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment duration of 1 to 2 years
Pharmacology, Toxicology and Pharmaceutical Science
6
9%
Nursing and Health Professions
3
5%
Agricultural and Biological Sciences
2
3%
Engineering
2
3%
Other
3
5%
Unknown
32
50%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 January 2021.
All research outputs
#9,515,768
of 27,788,362 outputs
Outputs from Journal of Clinical Lipidology
#618
of 1,259 outputs
Outputs of similar age
#131,173
of 338,469 outputs
Outputs of similar age from Journal of Clinical Lipidology
#35
of 55 outputs
Altmetric has tracked 27,788,362 research outputs across all sources so far. This one is in the 42nd percentile – i.e., 42% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,259 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 13.2. This one is in the 42nd percentile – i.e., 42% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 338,469 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.
We're also able to compare this research output to 55 others from the same source and published within six weeks on either side of this one. This one is in the 30th percentile – i.e., 30% of its contemporaries scored the same or lower than it.
